At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
AKB-6548drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4
In Brief
A Phase 2 clinical trial evaluating AKB-6548 for Anemia and Kidney Disease. Completed, enrolled 10 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Kidney Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedNov 2010
Primary CompletionApr 2011
Study CompletionMay 2011
TodayJul 2026
First PostedNov 8, 2010
Enrollment StartOct 21, 2010
Primary CompletionApr 13, 2011
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.7 years ago
Interventions
AKB-6548drug
Different dose levels